Compare BXSL & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BXSL | BLLN |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | United States |
| Employees | N/A | 713 |
| Industry | Trusts Except Educational Religious and Charitable | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.8B |
| IPO Year | 2018 | N/A |
| Metric | BXSL | BLLN |
|---|---|---|
| Price | $23.17 | $139.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 7 |
| Target Price | $27.18 | ★ $126.71 |
| AVG Volume (30 Days) | ★ 1.6M | 593.0K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 12.87% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $46.29 |
| Revenue Next Year | N/A | $30.14 |
| P/E Ratio | $211.32 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.47 | $61.96 |
| 52 Week High | $31.41 | $139.79 |
| Indicator | BXSL | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 44.60 | 63.32 |
| Support Level | $22.47 | $79.07 |
| Resistance Level | $24.84 | $138.70 |
| Average True Range (ATR) | 0.42 | 7.53 |
| MACD | -0.03 | -0.04 |
| Stochastic Oscillator | 23.94 | 81.68 |
Blackstone Secured Lending Fund is a non-diversified, closed-end management investment company. The investment objectives of the company are to generate current income and, to a lesser extent, long-term capital appreciation. The company seeks to achieve its investment objectives by investing in originated loans and other securities, including syndicated loans of private U.S. companies, typically in the form of first lien senior secured and unitranche loans, unsecured and subordinated loans, and other securities. The company operates as a single reportable segment and derives revenues from investing in originated loans and other securities, including broadly syndicated loans, of U.S. private companies.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.